title: [Immunomodulatory properties of stem mesenchymal cells in autoimmune diseases].
abstract: Autoimmune diseases are a cluster of disorders characterized by a failure of the immune tolerance and a hyperactivation of the immune system that leads to a chronic inflammation state and the damage of several organs. The medications currently used to treat these diseases usually consist of immunosuppressive drugs that have significant systemic toxic effects and are associated with an increased risk of opportunistic infections. Recently, several studies have demonstrated that mesenchymal stem cells have immunomodulatory properties, a feature that make them candidates to be used in the treatment of autoimmune diseases. In the present study, we reviewed the role of this therapy in the treatment of systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, Crohn's disease and multiple sclerosis, as well as the potential risks associated with its use.
authors.affiliation: Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, España. Electronic address: isabelsanchezberna@gmail.com.
authors.forename: Isabel
authors.initials: I
authors.lastname: Sánchez-Berná
authors.affiliation: Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Santiago-Díaz
authors.affiliation: Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, España.
authors.forename: Juan
authors.initials: J
authors.lastname: Jiménez-Alonso
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000628:therapy*; D002471:Cell Transformation, Neoplastic; D002828:Choristoma / Q000209:etiology; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy; D004195:Disease Models, Animal; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D045164:Mesenchymal Stem Cell Transplantation / Q000009:adverse effects; D059630:Mesenchymal Stem Cells / Q000276:immunology / Q000502:physiology*; D051379:Mice; D019463:Mice, Inbred MRL lpr; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy; D009894:Opportunistic Infections / Q000209:etiology; D012595:Scleroderma, Systemic / Q000276:immunology / Q000628:therapy; D012859:Sjogren's Syndrome / Q000276:immunology / Q000628:therapy
chemical_list: D000954:Antigens, Surface; D007166:Immunosuppressive Agents
keywords: Autoimmune diseases; Células madre mesenquimales; Enfermedades autoinmunes; Enfermedades autoinmunitarias; Immunomodulation; Inmunomodulación; Mesenchymal stem cells